We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TRIENTINE DR.REDDY'S, TRIENTINE-DRLA, TRIENTINE-REDDY'S, TRIENTINE-RZ (Dr Reddys Laboratories Australia Pty Ltd)
Product name
TRIENTINE DR.REDDY'S, TRIENTINE-DRLA, TRIENTINE-REDDY'S, TRIENTINE-RZ
Date registered
Evaluation commenced
Decision date
Approval time
160 (255 working days)
Active ingredients
trientine dihydrochloride
Registration type
NCE/NBE
Indication
TRIENTINE DR.REDDY'S, TRIENTINE-DRLA, TRIENTINE-REDDY'S, TRIENTINE-RZ (capsule) are indicated for the treatment of patients with Wilson's disease who are intolerant of penicillamine.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.